手术治疗伊马替尼耐药后肿瘤局部进展胃肠道间质瘤患者的疗效观察  

Surgical treatment for locally advanced, imatinib-resistant gastrointestinal stromal tumor

作　　者：成驰 孙林德[1] 徐文通[1] CHENG Chi;SUN Linde;XU Wentong(Department of General Surgery,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院普通外科,北京100853

出　　处：《解放军医学院学报》2018年第11期944-946,954,共4页Academic Journal of Chinese PLA Medical School

摘　　要：目的评价手术治疗伊马替尼耐药后肿瘤局部进展胃肠道间质瘤患者的效果。方法回顾性分析2006年1月-2017年9月本院收治的34例伊马替尼治疗耐药后肿瘤局部进展胃肠道间质瘤患者。其中24例接受手术联合伊马替尼治疗(联合组),10例患者单纯接受伊马替尼治疗(单药组),比较两组患者的治疗获益的情况,包括无进展生存期(progression-free survival,PFS)及总生存期(overall survival,OS),比较手术+药物与单纯药物治疗伊马替尼耐药后肿瘤局部进展的胃肠道间质瘤患者的疗效。结果两组患者的性别,年龄、肿瘤的原发部位等均无统计学差异(P均> 0.05),联合组患者的PFS及OS均要优于单药组(PFS:17.8个月vs 10.5个月,P=0.019;OS:48.9个月vs 30.7个月;P=0.011)。结论手术联合药物治疗对伊马替尼耐药的局部肿瘤进展胃肠道间质瘤患者的临床效果要优于单纯药物治疗。Objective To evaluate the effect of surgical treatment for patients with locally advanced,imatinib-resistant gastrointestinal stromal tumors (GIST).Methods A retrospective analysis was performed in 34 patients with locally advanced,imatinib-resistant gastrointestinal stromal tumors treated in our hospital from January 2009 to September 2017.Of the 34 cases,24 patients underwent surgery combined with imatinib treatment served as combinative treatment group,and 10 patients received imatinib alone as imatinib group.The treatment benefit of the two groups was compared,including progression-free survival (PFS)and overall survival (OS).Results There was no significant difference in gender,age and primary site of the tumor between the two groups (all P >0.05).The PFS and OS of the combinative treatment group were longer than those of imatinib group (PFS,17.8 months vs 10.5 months,P=0.019;OS,48.9 months vs 30.7 months,P=0.011).Conclusion The clinical effect of surgery combined with imatinib is superior to drug therapy alone on patients with locally advanced,imatinib-resistant gastrointestinal stromal tumors.

关 键 词：晚期间质瘤 耐药 手术 酪氨酸酶抑制剂 

分 类 号：R735[医药卫生—肿瘤]